Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) and Innovus Pharmaceuticals (NASDAQ:INNV) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership.

Profitability

This table compares Tonix Pharmaceuticals Holding Corp. and Innovus Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tonix Pharmaceuticals Holding Corp. N/A -84.89% -78.71%
Innovus Pharmaceuticals -116.92% -493.09% -116.77%

Institutional & Insider Ownership

17.5% of Tonix Pharmaceuticals Holding Corp. shares are held by institutional investors. 4.0% of Tonix Pharmaceuticals Holding Corp. shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Tonix Pharmaceuticals Holding Corp. and Innovus Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Tonix Pharmaceuticals Holding Corp. N/A N/A -$24.36 million ($6.90) -0.54
Innovus Pharmaceuticals $7.79 million N/A -$6.28 million N/A N/A

Innovus Pharmaceuticals has higher revenue and earnings than Tonix Pharmaceuticals Holding Corp..

Analyst Ratings

This is a breakdown of current recommendations and price targets for Tonix Pharmaceuticals Holding Corp. and Innovus Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tonix Pharmaceuticals Holding Corp. 0 2 4 0 2.67
Innovus Pharmaceuticals 0 0 0 0 N/A

Tonix Pharmaceuticals Holding Corp. presently has a consensus target price of $8.33, suggesting a potential upside of 122.22%. Given Tonix Pharmaceuticals Holding Corp.’s higher probable upside, analysts clearly believe Tonix Pharmaceuticals Holding Corp. is more favorable than Innovus Pharmaceuticals.

Summary

Tonix Pharmaceuticals Holding Corp. beats Innovus Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

Tonix Pharmaceuticals Holding Corp. Company Profile

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden. Its lead product candidate includes TNX-102 SL, a cyclobenzaprine HCl sublingual tablet, which is in Phase III clinical stage for the treatment of PTSD; and Phase III clinical stage for the treatment of military-related PTSD. The company’s product candidates also include TNX-601, an oral formulation of tianeptine oxalate for PTSD and cognitive dysfunction associated with steroid use; TNX-801, a smallpox-preventing vaccine based on a live synthetic version of horsepox virus; TNX-301, a fixed-dose combination drug product for alcohol use disorders; and TNX-701 for radiation injuries. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.

Innovus Pharmaceuticals Company Profile

Innovus Pharmaceuticals, Inc. is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners. It has commercial agreements in over 60 countries around the world through its commercial partners. Its marketed products include Zestra, EjectDelay, Sensum+, Zestra Glide, Vesele and Androferti. In addition, the Company has a pipeline of over three additional products, including FlutiCare Over-The-Counter (OTC) for Allergic Rhinitis; Urocis XR, an extended release of Vaccinium Marcocarpon (cranberry), and AndroVit, a supplement to support overall prostate and male sexual health, which is marketed in Europe.

Receive News & Stock Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related stocks with our FREE daily email newsletter.